Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T‐lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia.
- Resource Type
- Article
- Source
- Pediatric Blood & Cancer; Jun2024, Vol. 71 Issue 6, p1-3, 3p
- Subject
- Language
- ISSN
- 15455009